J Biol Chem 275:1325913265 Brandsma D, Kerklaan BM, Diras V, Altintas S, Anders CK, Ballester MA, Gelderblom H, Soetekouw PMMB, Gladdines W, Lonnqvist F et al (2014) Phase 1/2a study of glutathione pegylated liposomal doxorubicin (2b3-101) in patients with brain metastases (BM) from solid tumors or recurrent high grade gliomas (HGG)
Indeed, Rossignol and Frye (Rossignol and Frye, 2021) examined studies linking cerebral folate deficiency to ASD
For clinicians and patients, the practical timeline matters: CagriSema is closer to potential approval (phase 3 complete), while amycretin's phase 3 is planned for 2026
Caregivers also play an important role in tracking symptom patterns